FDA Approves Olaparib for Certain Metastatic Prostate Cancers FDA Approves Olaparib for Certain Metastatic Prostate Cancers

Another PARP inhibitor, Lynparza, has been approved for use in prostate cancer.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Related Links:

More News: Cancer | Cancer & Oncology | Health | Hematology | Prostate Cancer